A cleavage enzyme-cytometric bead array provides biochemical profiling of resistance mutations in HIV-1 Gag and protease

Biochemistry

Volumn 50, Issue 20, 2011, Pages 4371-4381

  Breuer, Sebastian ^a   Sepulveda, Homero ^b   Chen, Yu ^b   Trotter, Joseph ^b   Torbett, Bruce E ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b BD BIOSCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL PROFILING; CATALYTIC EFFICIENCIES; CLEAVAGE SITES; ENZYMATIC CLEAVAGE; FLUORESCENT REPORTER; FUSION PROTEINS; HIV-1 PROTEASE; PROTEASE INHIBITOR; SITE LOCATION; SMALL MOLECULE INHIBITOR; SUBSTRATE STRUCTURE; SYNTHETIC PEPTIDE SUBSTRATE;

ASSAYS; ENZYME INHIBITION; FLOW CYTOMETRY; FLUORESCENCE;

SUBSTRATES;

GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; HYBRID PROTEIN; PROTEINASE; PROTEINASE INHIBITOR;

ARTICLE; BIOCHEMISTRY; CELL STRAIN HEK293; ENZYME ASSAY; ENZYME CYTOMETRIC BEAD ARRAY; ENZYME KINETICS; ENZYME SUBSTRATE; FEMALE; FLOW CYTOMETRY; GENETIC TRANSFECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IC 50; MUTATION; PLASMID; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN IMMOBILIZATION; RESISTANCE MUTATION; SCANNING ELECTRON MICROSCOPY; VIRUS ISOLATION;

BINDING SITES; DRUG RESISTANCE, VIRAL; ENZYME ASSAYS; FLOW CYTOMETRY; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIGH-THROUGHPUT SCREENING ASSAYS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; KINETICS; MICROSPHERES; MUTATION; RECOMBINANT FUSION PROTEINS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79956196738     PISSN: 00062960     EISSN: 15204995     Source Type: Journal    
DOI: 10.1021/bi200031m     Document Type: Article

References (41)

1. Rawlings, N. D., Tolle, D. P., and Barrett, A. J. (2004) MEROPS: the peptidase database Nucleic Acids Res. 32, D160-164
2. Puente, X. S., Sanchez, L. M., Overall, C. M., and Lopez-Otin, C. (2003) Human and mouse proteases: a comparative genomic approach Nat. Rev. Genet. 4, 544-558 (Pubitemid 36781345)
3. Turk, B. (2006) Targeting proteases: successes, failures and future prospects Nat. Rev. Drug Discovery 5, 785-799 (Pubitemid 44323703)
4. Abbenante, G. and Fairlie, D. P. (2005) Protease inhibitors in the clinic Med. Chem. 1, 71-104
5. Flexner, C. (2007) HIV drug development: the next 25 years Nat. Rev. Drug Discovery 6, 959-966 (Pubitemid 350201786)
6. Colonno, R., Rose, R., McLaren, C., Thiry, A., Parkin, N., and Friborg, J. (2004) Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens J. Infect. Dis. 189, 1802-1810 (Pubitemid 38657216)
7. Zennou, V., Mammano, F., Paulous, S., Mathez, D., and Clavel, F. (1998) Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo J. Virol. 72, 3300-3306 (Pubitemid 28175575)
8. Condra, J. H., Schleif, W. A., Blahy, O. M., Gabryelski, L. J., Graham, D. J., Quintero, J. C., Rhodes, A., Robbins, H. L., Roth, E., and Shivaprakash, M. 1995, In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors Nature 374, 569-571
9. Feher, A., Weber, I. T., Bagossi, P., Boross, P., Mahalingam, B., Louis, J. M., Copeland, T. D., Torshin, I. Y., Harrison, R. W., and Tozser, J. (2002) Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites Eur. J. Biochem. 269, 4114-4120 (Pubitemid 34994906)
10. Nijhuis, M., Schuurman, R., de Jong, D., Erickson, J., Gustchina, E., Albert, J., Schipper, P., Gulnik, S., and Boucher, C. A. (1999) Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy AIDS 13, 2349-2359
11. Nijhuis, M., van Maarseveen, N. M., Lastere, S., Schipper, P., Coakley, E., Glass, B., Rovenska, M., de Jong, D., Chappey, C., Goedegebuure, I. W., Heilek-Snyder, G., Dulude, D., Cammack, N., Brakier-Gingras, L., Konvalinka, J., Parkin, N., Krausslich, H. G., Brun-Vezinet, F., and Boucher, C. A. (2007) A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism PLoS Med. 4, e36
12. Ho, S. K., Coman, R. M., Bunger, J. C., Rose, S. L., OBrien, P., Munoz, I., Dunn, B. M., Sleasman, J. W., and Goodenow, M. M. (2008) Drug-associated changes in amino acid residues in Gag p2, p7(NC), and p6(Gag)/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response Virology 378, 272-281
13. Ho, S. K., Perez, E. E., Rose, S. L., Coman, R. M., Lowe, A. C., Hou, W., Ma, C., Lawrence, R. M., Dunn, B. M., Sleasman, J. W., and Goodenow, M. M. (2009) Genetic determinants in HIV-1 Gag and Env V3 are related to viral response to combination antiretroviral therapy with a protease inhibitor AIDS 23, 1631-1640
14. Lambert-Niclot, S., Flandre, P., Malet, I., Canestri, A., Soulie, C., Tubiana, R., Brunet, C., Wirden, M., Katlama, C., Calvez, V., and Marcelin, A. G. (2008) Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease J. Antimicrob. Chemother. 62, 905-908
15. Dam, E., Quercia, R., Glass, B., Descamps, D., Launay, O., Duval, X., Krausslich, H. G., Hance, A. J., and Clavel, F. (2009) Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss PLoS Pathog. 5 e1000345
16. Klabe, R. M., Bacheler, L. T., Ala, P. J., Erickson-Viitanen, S., and Meek, J. L. (1998) Resistance to HIV protease inhibitors: a comparison of enzyme inhibition and antiviral potency Biochemistry 37, 8735-8742 (Pubitemid 28299611)
17. Prabu-Jeyabalan, M., Nalivaika, E., and Schiffer, C. A. (2000) How does a symmetric dimer recognize an asymmetric substrate? A substrate complex of HIV-1 protease J. Mol. Biol. 301, 1207-1220
18. Pettit, S. C., Henderson, G. J., Schiffer, C. A., and Swanstrom, R. (2002) Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease J. Virol. 76, 10226-10233
19. Doyon, L., Croteau, G., Thibeault, D., Poulin, F., Pilote, L., and Lamarre, D. (1996) Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors J. Virol. 70, 3763-3769 (Pubitemid 26161824)
20. Dunn, B. M., Gustchina, A., Wlodawer, A., and Kay, J. (1994) Subsite preferences of retroviral proteinases Methods Enzymol. 241, 254-278
21. Bally, F., Martinez, R., Peters, S., Sudre, P., and Telenti, A. (2000) Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors AIDS Res. Hum. Retroviruses 16, 1209-1213
22. Saunders, M. J., Kim, H., Woods, T. A., Nolan, J. P., Sklar, L. A., Edwards, B. S., and Graves, S. W. (2006) Microsphere-based protease assays and screening application for lethal factor and factor Xa Cytometry, Part A 69, 342-352 (Pubitemid 44651347)
23. Morrison, J. F. (1969) Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors Biochim. Biophys. Acta 185, 269-286
24. Giffin, M. J., Heaslet, H., Brik, A., Lin, Y. C., Cauvi, G., Wong, C. H., McRee, D. E., Elder, J. H., Stout, C. D., and Torbett, B. E. (2008) A copper(I)-catalyzed 1,2,3-triazole azide-alkyne click compound is a potent inhibitor of a multidrug-resistant HIV-1 protease variant J. Med. Chem. 51, 6263-6270
25. Kuckuck, F. W., Edwards, B. S., and Sklar, L. A. (2001) High throughput flow cytometry Interface 90, 83-90 (Pubitemid 32434006)
26. Surawski, P. P., Battersby, B. J., Lawrie, G. A., Ford, K., Ruhmann, A., Marcon, L., Kozak, D., and Trau, M. (2008) Flow cytometric detection of proteolysis in peptide libraries synthesised on optically encoded supports Mol. BioSyst. 4, 774-778 (Pubitemid 351871750)
27. Harper, S. and Speicher, D. W. (2008) Expression and purification of GST fusion proteins. Curr. Protoc. Protein Sci. Chapter 6, Unit 6 6.
28. Nagai, T., Ibata, K., Park, E. S., Kubota, M., Mikoshiba, K., and Miyawaki, A. (2001) A variant of yellow fluorescent protein with fast and efficient maturation for cell-biological application Nature 20, 1585-1588
29. Shaner, N. C., Steinbach, P. A., and Tsien, R. Y. (2005) A guide to choosing fluorescent proteins Nat. Methods 2, 905-909 (Pubitemid 43108726)
30. Zacharias, D. A., Violin, J. D., Newton, A. C., and Tsien, R. Y. (2002) Partitioning of lipid-modified monomeric GFPs into membrane microdomains of live cells Science 296, 913-916 (Pubitemid 34464897)
31. Pettit, S. C., Henderson, G. J., Schiffer, C. A., and Swanstrom, R. (2002) Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease J. Virol. 76, 10226-10233
32. Lee, S. K., Harris, J., and Swanstrom, R. (2009) A strongly transdominant mutation in the human immunodeficiency virus type 1 gag gene defines an Achilles heel in the virus life cycle J. Virol. 83, 8536-8543
33. Nalam, M. N. and Schiffer, C. A. (2008) New approaches to HIV protease inhibitor drug design II: testing the substrate envelope hypothesis to avoid drug resistance and discover robust inhibitors Curr. Opin. HIV AIDS 3, 642-646
34. Buhler, B., Lin, Y. C., Morris, G., Olson, A. J., Wong, C. H., Richman, D. D., Elder, J. H., and Torbett, B. E. (2001) Viral evolution in response to the broad-based retroviral protease inhibitor TL-3 J. Virol. 75, 9502-9508 (Pubitemid 32851952)
35. Markowitz, M., Mo, H., Kempf, D. J., Norbeck, D. W., Bhat, T. N., Erickson, J. W., and Ho, D. D. (1995) Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor J. Virol. 69, 701-706
36. Muzammil, S., Ross, P., and Freire, E. (2003) A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance Biochemistry 42, 631-638 (Pubitemid 36133287)
37. Myint, L., Matsuda, M., Matsuda, Z., Yokomaku, Y., Chiba, T., Okano, A., Yamada, K., and Sugiura, W. (2004) Gag non-cleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistant human immunodeficiency virus type 1 Antimicrob. Agents Chemother. 48, 444-452 (Pubitemid 38141700)
38. Mayr, L. M. and Bojanic, D. (2009) Novel trends in high-throughput screening Curr. Opin. Pharmacol. 9, 580-588
39. Zhang, J. H., Chung, T. D., and Oldenburg, K. R. (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays J. Biomol. Screening 4, 67-73 (Pubitemid 29278954)
40. Copeland, R. A. (2003) Mechanistic considerations in high-throughput screening Anal. Biochem. 320, 1-12 (Pubitemid 36937062)
41. Shoichet, B. K. (2006) Screening in a spirit haunted world Drug Discovery Today 11, 607-615